Tharimmune, Inc. Files Material Definitive Agreement 8-K

Ticker: CNTN · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1861657

Tharimmune, INC. 8-K Filing Summary
FieldDetail
CompanyTharimmune, INC. (CNTN)
Form Type8-K
Filed DateJun 7, 2024
Risk Levelmedium
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, corporate-action

TL;DR

THARIMMUNE (THAR) filed an 8-K for a new material agreement. Details TBD.

AI Summary

On June 7, 2024, Tharimmune, Inc. filed an 8-K report detailing a material definitive agreement. The company, formerly known as Hillstream BioPharma Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. The filing does not disclose specific details of the agreement or any associated dollar amounts.

Why It Matters

This filing indicates a significant new agreement for Tharimmune, Inc., which could impact its business operations and future financial performance.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could be significant, but lacks specific details, creating uncertainty.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement filed by Tharimmune, Inc.?

The filing does not specify the nature of the material definitive agreement.

When was this material definitive agreement entered into?

The filing reports the date of the earliest event reported as June 7, 2024, which is the date of the report.

What was Tharimmune, Inc.'s former company name?

Tharimmune, Inc.'s former company name was Hillstream BioPharma Inc.

In which state is Tharimmune, Inc. incorporated?

Tharimmune, Inc. is incorporated in Delaware.

What is Tharimmune, Inc.'s Standard Industrial Classification code?

Tharimmune, Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 898 words · 4 min read · ~3 pages · Grade level 11.8 · Accepted 2024-06-07 17:23:08

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 7, 2024 Tharimmune, Inc. /s/ Randy Milby Randy Milby Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing